UK Markets close in 6 hrs 15 mins

TheraVet SA (ALVET.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
5.10-0.10 (-1.92%)
As of 09:31AM CET. Market open.
Full screen
Previous close5.20
BidN/A x N/A
AskN/A x N/A
Day's range5.10 - 5.40
52-week range4.98 - 8.56
Avg. volume2,242
Market cap16.442M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.00
  • Business Wire

    TheraVet Provides Its 2021 Second Half Operational Update

    GOSSELIES, Belgium, January 25, 2022--Regulatory News: TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 - ticker: ALVET), a pioneering biotechnology company specialising in the management of osteoarticular diseases in pets, presents its half-year operational update ending December 31, 2021.

  • Business Wire

    TheraVet Strengthens Its Sales Organisation in France by Signing an Important Distribution Agreement for BIOCERA-VET®

    GOSSELIES, Belgium, January 18, 2022--Regulatory News: TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 - ticker: ALVET), a biotech company developing pioneering treatments for osteoarticular disease in pets, announced today the signature of a non-exclusive commercial distribution agreement for its BIOCERA-VET® bone substitute in France with the veterinary co-operative Centravet, one of France’s leading wholesaler/distributors of animal health products. The agreement covers the BIOCER

  • Business Wire

    TheraVet Announces the Initiation of Coverage of Its Stock by Degroof Petercam

    GOSSELIES, Belgique, January 10, 2022--Regulatory News: TheraVet (code ISIN: BE0974387194 - mnémonique: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, announces today the initiation of commissioned research coverage of its title by Degroof Petercam, with a study entitled "Revolutionizing the treatment of osteoarticular diseases".